Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis thelancet.com/journals/lanon…

The role of adjuvant radiotherapy for #breastcancer is more nuanced than the binary decision whether or not to radiate. Genomics will help guide personalized medicine. #radonc Javier F Torres-Roca advancesradonc.org/article/S2452-…

Various healthcare professionals join to discuss the management of a patient diagnosed with HER2-positive breast cancer and consider how to best approach newer treatment strategies through her continuum of care. #bcsm | Kamran Ahmed ow.ly/JfPw50IuncR

Great trial led by Kamran Ahmed in the Department of Radiation Oncology Moffitt Cancer Center

Honored to work with awesome Team and present DRIVE Multicenter Study #ASTRO2022 on dose-escalated (>=64Gy) RT in Vulvar Cancer: cCR >81%, 5yr LRC 73%, 90% compliance. Thx ASTRO for recognizing our work with clinical 'recognition' and 'Abstract Award'

In recognition of #CervicalCancerAwarenessMonth, our latest podcast episode is on updates in cervical cancer! Listen here: 🎧ow.ly/YFqn50MvUHF🎧 #CervicalCancer #GyncSM #GynOnc UC San Diego Rad Med UMich Rad Onc Kamran Ahmed

Thank you PDBrown ! Daniel (Donny) Oliver Matthew Mills Michael Vogelbaum

Some of the interesting work Moffitt Cancer Center, optimizing RT dose strategies for Sarcoma and Breast Cancer. Utilizing GARD and going HARD at Soft tissue sarcoma! Thanks Kerri Reeves and Applied Radiation Oncology Kamran Ahmed James Caudell MoffittRadOnc appliedradiationoncology.com/articles/getti…

Great work from incoming UMich Rad Onc resident Joseph D. Tang and MoffittRadOnc Matthew Mills Justyn Nakashima, DO Ammoren Dohm MD on combining SRS with Nivo/Ipi for melanoma brain mets Daniel (Donny) Oliver Evan Wuthrick James K. C. Liu Michael Vogelbaum Moffitt Cancer Center

Dr Sarah Sammons Kamran Ahmed is running an MRI screening trial Moffitt Cancer Center in this and other breast cancer populations. Great data. Catching brain mets early may open up opportunities for SRS or targeted agents to improve outcomes.

Phase I results from our study of RT + IT T/P for HER2+ LMD now online JAMA Oncology. Phase II study currently open Moffitt Cancer Center and Lurie Cancer Center. Great collaborative effort! Peter Forsyth Yoly (Yolanda) Pina Michael Vogelbaum Daniel (Donny) Oliver James K. C. Liu MoffittRadOnc James Caudell

Combining two cancer drugs may be a promising treatment for advanced metastatic #breastcancer, according to the results of a clinical trial co-authored by Lurie Cancer Center’s Priya Kumthekar, MD, in Journal of Clinical Investigation. news.feinberg.northwestern.edu/2024/06/14/com… #bcsm

Excellent work in a much needed space for our patients with LMD from HER2+ breast cancer. Kamran Ahmed Yoly (Yolanda) Pina Moffitt Cancer Center

Our chair, Dr. Kosj Yamoah, opens up our departmental FORT Retreat meeting! 🧬 Kosj Yamoah MD, PhD Moffitt Cancer Center Kamran Ahmed

Saddened to hear of the passing of friend & mentor Jeff Weber NYU Langone Health Thank you for being an exemplary teacher, & igniting with Jedd Wolchok my interest in immune tox. Thank you for teaching me how to write a paper. I still read those notes at least once a year. Rest in Peace

Interesting and hypothesis provoking research letter in JAMA Oncology - Narjust Florez, MD, FASCO Moffitt Cancer Center Kamran Ahmed oncodaily.com/insight/127173 #Cancer #ClinicalTrials #HER2 #CancerResearch #OncoDaily #Oncology

ASCO SNO 2024 Brain Mets Conference: Record-Breaking Attendance. Moffitt Cancer Center Milestone Achievement! Sessions led by Dr. Pina & Dr. Forsyth. Presentations by: Dr. Ahmed, Dr. Forsyth, Dr. Oliver, Dr. Pina, Dr. Smalley, & Vincent Law. Moffitt Ambassador: Dr. Grogan